Cheap, 'generic' drug reduces COVID-19 death risk by 75 percent, trials suggest
Ivermectin, a cheap and "generic" antiparasitic drug "used all over the world," may significantly reduce the risk of death in patients suffering from moderate to severe cases of COVID-19, researchers have found.
The University of Liverpool's Andrew Hill and others carried out a meta-analytical breakdown of 18 studies that showed the drug — which is off-patent and commonly used to treat lice and scabies, as well as some more serious parasites — appears to reduce inflammation and eliminate the coronavirus swiftly, the Financial Times reports. In six of those trials, the mortality risk was cut by 75 percent in patients with more serious COVID-19 infections. The research team has also theorized the drug could also make it harder for infected people to transmit the virus.
Hill said he's encouraged by the findings, but further studies are needed, especially since several of those in the analysis were not peer-reviewed. FT also notes that meta-analyses, which look at many studies at once, can be prone to errors. Read more at the Financial Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Best TV shows coming in 2025
The Week Recommends From Wild Cherry to The Bear, next year's most anticipated new and returning watches
By Tess Foley-Cox Published
-
Sudan's forgotten pyramids
Under the Radar Brutal civil war and widespread looting threatens African nation's ancient heritage
By Harriet Marsden, The Week UK Published
-
'Being more nuanced will not be easy for public health agencies'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published